← Back to the Investment Managers Blog

Investors Chronicle includes Trust in top 100 funds

Published on 20th September 2019

Science background with molecule or atom Abstract structure for Science or medical background
Science background with molecule or atom Abstract structure for Science or medical background

I am pleased to present International Biotechnology Trust’s factsheet for August 2019.

The end of August marks six years since I joined International Biotechnology Trust as Lead Investment Manager. Over this time period, the Trust has returned 168.7% (share price, total return) and 125.4% (net asset value, total return), equal to an annualised return of 17.9% and 14.5% respectively. I am pleased the investment community continues to recognise our outperformance of both the benchmark and our competitors. For example, the Trust was recently recognised in the Investors Chronicle’s Top 100 Funds: Investors Chronicle Top 100

So, with good historical performance behind us, what does the future hold? As I’ve said many times, it is difficult to predict future market direction and I will refrain from doing so. I will instead cite the investment bank Cowen; whose 2019 September Therapeutic Categories Outlook predicts that the worldwide biotherapeutics industry will deliver mid-single digit annual sales growth to 2024. One would therefore expect this to translate into even higher earnings growth. It seems, then, that the biotechnology sector is still in favourable waters with stable tailwinds.

That said, companies within the sector are certainly not over-valued. Far from it, in fact. Let me exemplify with our largest holding, Gilead, a company with a market cap of over $80bn, which currently makes up c. 7% of the Trust. Gilead’s main business is drugs for HIV. This business is stable, even though that is an unfortunate fact for many patients around the world. There is still no cure for HIV and it is not going away any time soon. As a result, Gilead’s predicted price/earnings ratio for 2020 is approx. 9.5 and EV/revenue in 2020 is 3.6. This profitability allows Gilead to pay a dividend of 3.8%. These ratios all compare favourably to the S&P 500 Index, whose predicted P/E multiple for 2020 is 16.5 (Source: Bloomberg).

Thank you for taking the time to read our factsheet.

August Factsheet (click link to open)


The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

The material on this website is intended to be viewed only by persons resident in the UK.

The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).

I do not accept →